
Opinion|Videos|July 29, 2024
Identifying Patients Eligible for RSV Vaccine
Experts from clinical and payer backgrounds discuss how patients eligible for the RSV vaccine can be identified.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- How have eligible patients for the RSV vaccine been identified in pharmacies and health systems? Have RSV vaccines become annual immunizations like flu vaccines?
- Have electronic health records been built to identify eligible patients and incorporate RSV vaccines immunization records? How has the identification of eligible patients been implemented into workflow?
- From a payer perspective, how have you ensured eligible patients are identified for immunization?
- From a payer perspective, how have you ensured eligible patients are identified for immunization?
Advertisement
Related to this article

Employer-mandated enrollment in a high-deductible health plan did not reduce use of oral targeted anticancer medications among patients commercially insured between 2007 and 2021.

We identify the health system characteristics associated with greater or lesser documentation of patients’ social determinants of health.

MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.

This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.

This week in health equity and access: PMOS diagnosis, HIV lung cancer screening, transplant access, atopic dermatitis care, and value-based oncology.

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
4
Who Recommends COVID-19 Vaccines Without ACIP?
5


